Navigation Links
NeuroDerm Announces Presentation of ND0612 Phase 1 and Phase 2 Results at the 2013 International Congress of Parkinson's Disease and Movement Disorders
Date:6/13/2013

NESS ZIONA, Israel, June 13, 2013 /PRNewswire/ --

NeuroDerm, Ltd. today announced that abstracts reporting results from a phase I study in healthy volunteers, and preliminary results from a phase IIA study in advanced Parkinson's patients, of ND0612, have been selected for presentation  at the 17th International Congress of Parkinson's Disease and Movement Disorders, June 16th-20th in Sydney, Australia.

ND0612 is a proprietary levodopa/carbidopa liquid drug formula under development for continuous administration through a sub-cutaneous (SC) delivery patch that would maintain constant levodopa plasma concentrations.

Details on the Presentations are as follows:

Title: Constant Therapeutic Levodopa Plasma Concentrations Maintained by Continuous Subcutaneous Administration of ND−0612, a Novel Formulation of Levodopa/Carbidopa
Abstract #: 452
Presenter: Peter LeWitt
Poster session: Parkinson's Disease: Clinical Trials
Date and time: Tuesday, June 18th, 12:30pm
Location: Bayside, level, 1 gallery B

Title: ND0612, A Novel Formulation of Levodopa/Carbidopa for Continuous, Subcutaneous Administration, Achieves Steady-State Levodopa Plasma Concentrations in Parkinson's Disease Patients
Abstract #: LBA26
Presenter: Nir Giladi
Poster session: Late Breaking Abstracts
Date and time: Wednesday, June 19th, 12:00pm
Location: Exhibit hall #5

About NeuroDerm

NeuroDerm is an emerging pharmaceutical company that develops therapies for the treatment of CNS diseases. NeuroDerm's technology is based on proprietary reformulations of well-established oral drugs that achieve better efficacy. The company's lead products are ND0612, a novel sub-cutaneous drug formulation for the treatment of Parkinson's disease, and ND0801, a combination drug for the treatment of cognitive disorders in diseases such as ADD/ADHD, schizophrenia and Alzheimer's disease. NeuroDerm is headquartered in the Weizmann Science Park, Ness Ziona, Israel.

Contact:
Oded S. Lieberman, PhD MBA, Chairman & CEO
oded@neuroderm.com
Tel.: +972-8-946 2729; Cell: +1-617-517-6077


'/>"/>
SOURCE NeuroDerm Ltd
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. NeuroDerm Awarded $1M by The Michael J. Fox Foundation for the Clinical Development of ND0612 for Parkinsons Disease
2. NeuroDerm to Present at the Jefferies 2013 Global Healthcare Conference in New York City
3. NeuroDerm Announces Positive Results of a Phase I Study of ND0612 for the Treatment of Parkinsons Disease
4. NeuroDerm Announces Enrollment in a Phase 1 Study of ND0612, a Continuous Levodopa/Carbidopa Drug for the Treatment of Parkinsons Disease
5. Royalty Pharma Announces Offer May Lapse (Be Withdrawn)
6. Anthera Pharmaceuticals Announces Personnel Changes
7. Generex Announces Interview of MD Andersons Dr. Elizabeth Mittendorf, Principal Investigator on Companys AE37 Phase IIb Breast Cancer Efficacy Trial
8. Amgen Announces Top-Line Results Of Phase 3 Trebananib (AMG 386) TRINOVA-1 Trial In Recurrent Ovarian Cancer
9. HeartWare International Announces Intention To Delist From Australian Securities Exchange (ASX)
10. Misonix, Inc. Announces the Grant of Patent by the United States Patent and Trademark Office
11. Mindray Announces Appointment of Three Members to Its Executive Team
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... Mich. , Dec. 5, 2016  Sharn Anesthesia ... preferred anesthesia sales and distribution partner for Salter Labs.  ... of the Year in recognition of outstanding sales performance. ... devices for respiratory and anesthesia care, including the market ... is also the master distributor of the Parker Flex-Tip® ...
(Date:12/5/2016)... TrainerMD , the first HIPAA compliant software collaboration platform for patients, ... . Styku, a California -based software ... world-class, real-time 3D body scanning and analysis. Together with its other ... and feel their health like never before. ... , , ...
(Date:12/5/2016)... PARSIPPANY, N.J. , Dec. 5, 2016 ... today announced preliminary safety and efficacy data from ... oral selective MDM2 inhibitor, suggesting that DS-3032 may ... relapsed/refractory acute myeloid leukemia (AML) and high-risk myelodysplastic ... part of the phase 1 study of DS-3032 were ...
Breaking Medicine Technology:
(Date:12/6/2016)... ... December 06, 2016 , ... GrekTek LLC, ( http://www.grektek.com ) ... ( http://kck.st/2g3a1so ) for the HealthyWatch, a new device to help patients manage ... the watch while sharing these events with caregivers in real time. ...
(Date:12/6/2016)... (PRWEB) , ... December 06, 2016 , ... 'Tis the ... disrupt daily routines. That means it's also the season when eating healthy, staying active, ... with diabetes) on schedule is harder to do. , "Shopping trips, parties and ...
(Date:12/6/2016)... ... December 06, 2016 , ... ... recount of a powerful woman's story of sacrifice and enlightenment. , ... published author, Carolyn Fryer. Always looking for creative outlets, Carolyn gravitated toward writing ...
(Date:12/6/2016)... ... 06, 2016 , ... TopConsumerReviews.com recently gave a best-in-class 5 star rating to ... give freedom to people who need help getting around. For some, advancing age has ... period of rehabilitation after an illness or accident. There is a wide variety of ...
(Date:12/6/2016)... ... December 06, 2016 , ... "Add realistic flares and ... flash, and flare from clip to clip with high quality 4K lens flare footage," ... Jewel contains 44 lens flares filmed on the RED Dragon. Utilizing the Dragon Sensor, ...
Breaking Medicine News(10 mins):